Journal article
Individualised prediction of drug resistance and seizure recurrence after medication withdrawal in people with juvenile myoclonic epilepsy: A systematic review and individual participant data meta-analysis
R Stevelink, D Al-Toma, FE Jansen, HJ Lamberink, AA Asadi-Pooya, M Farazdaghi, G Cação, S Jayalakshmi, A Patil, Ç Özkara, Ş Aydın, J Gesche, CP Beier, LJ Stephen, MJ Brodie, G Unnithan, A Radhakrishnan, J Höfler, E Trinka, R Krause Show all
Eclinicalmedicine | ELSEVIER | Published : 2022
Abstract
Background: A third of people with juvenile myoclonic epilepsy (JME) are drug-resistant. Three-quarters have a seizure relapse when attempting to withdraw anti-seizure medication (ASM) after achieving seizure-freedom. It is currently impossible to predict who is likely to become drug-resistant and safely withdraw treatment. We aimed to identify predictors of drug resistance and seizure recurrence to allow for individualised prediction of treatment outcomes in people with JME. Methods: We performed an individual participant data (IPD) meta-analysis based on a systematic search in EMBASE and PubMed – last updated on March 11, 2021 – including prospective and retrospective observational studies..
View full abstractGrants
Awarded by Seventh Framework Programme
Funding Acknowledgements
We are grateful to the MING fonds for supporting this project, a generous donation by parents of children with epilepsy, which provided funding for doctoral studies of RS. We would like to thank Dr. Giovanni Falcicchio (Department of Basic Medical Sciences, Neurosciences and Sense Organs, University Hospital of Bari "A. Moro", Bari, Italy) and Rachel Wales BSc (University of Glasgow) for help with data collection. The European Union Seventh Framework Programme (FP7/2007-2013) supported this work under grant agreement n 279062, as part of the EpiPGX project. The NIH supported this work through grant NIH K23 NS052468.